A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE III, OPEN-LABEL, RANDOMISED STUDY TO ASSESS THE EFFICACY AND SAFETY OF EXTENDED THERAPY WITH CAMIZESTRANT (AZD9833, A NEXT GENERATION, ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER) VERSUS STANDARD ENDOCRINE THERAPY (AROMATASE INHIBITOR OR TAMOXIFEN) IN PATIENTS WITH ER+/HER2- EARLY BREAST CANCER AND AN INTERMEDIATE OR HIGH RISK OF RECURRENCE WHO HAVE COMPLETED DEFINITIVE LOCOREGIONAL THERAPY AND AT LEAST 2 YEARS OF STANDARD ADJUVANT ENDOCRINE BASED THERAPY WITHOUT DISEASE RECURRENCE

Intervention/treatment:
CAMIZESTRANT (AZD9833)
Medical condition:
BREAST CANCER
Protocol code:
D8531C00002
Control number:
271710
Status:
Recruiting
Approved:
February 21, 2023
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT05774951
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 130 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Name
AstraZeneca Breast Cancer Study Locator Service
Role
CONTACT
Phone:
1-877-400-4655
Sponsor
ASTRAZENECA AB

Locations

Alberta

Research Site
Calgary, Alberta, T2N 4N2
WITHDRAWN

British Columbia

Research Site
Kelowna, British Columbia, V1Y 5L3
Active, not recruiting

Manitoba

Research Site
Winnipeg, Manitoba, R3E 0V9
Active, not recruiting

Ontario

Research Site
Barrie, Ontario, L4M 6M2
Active, not recruiting
Research Site
Ottawa, Ontario, K1H 8L6
WITHDRAWN
Research Site
Sault Ste. Marie, Ontario, P6A 0A8
Active, not recruiting
Research Site
Toronto, Ontario, M5G 1X5
Active, not recruiting
Research Site
Windsor, Ontario, N8W 2X3
Active, not recruiting

Quebec

Research Site
Chicoutimi, Quebec, G7H 5H6
Active, not recruiting
Research Site
Greenfield Park, Quebec, J4V 2H1
Active, not recruiting
Research Site
Montreal, Quebec, H1T 2M4
Active, not recruiting
Research Site
Montreal, Quebec, H2X 3E4
Active, not recruiting
Research Site
Montreal, Quebec, H4A 3J1
Active, not recruiting
Research Site
Saint-Jérôme, Quebec, J7Z 5T3
Active, not recruiting
Did you find what you were looking for?

Contacts and resources